Literature DB >> 19809540

The emerging low-dose therapy for advanced cancers.

Jahangir Satti1.   

Abstract

Generally minute doses of drugs have been prescribed in biotherapies, homeopathy, immunization and vaccinations for centuries. Now the use of low doses of drugs is on the rise to combat serious diseases such as advanced cancers around the world. This new therapeutic approach to address solid tumors and other advanced diseases is a departure from the conventional use of maximum dose protocol. A small dose of the prescribed drug is frequently administered in a continuous fashion, at regular intervals, either as a standard treatment or as a maintenance therapy for a long time. However, this new treatment method lacks any standard for drug quantization, dose fractionation, repetition frequency and duration of a treatment course for an individual patient. This paper reviews literature about metronomic therapy and discusses hormesis: both phenomena occur in low dose ranges. Better mathematical models, computer simulations, process optimization and clinical trials are warranted to fully exploit the potential of low dose metronomic therapy to cure chronic and complicated diseases. New protocols to standardize metronomic dosimetry will answer the age old questions related to hormesis and homeopathy. It appears that this new low-dose metronomic therapy will have far reaching effects in curing chronic diseases throughout the world.

Entities:  

Keywords:  apoptosis; homeopathy; hormesis; low-dose; metronomic

Year:  2009        PMID: 19809540      PMCID: PMC2754535          DOI: 10.2203/dose-response.08-010.Satti

Source DB:  PubMed          Journal:  Dose Response        ISSN: 1559-3258            Impact factor:   2.658


  64 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Mathematics and oncology: a match for life?

Authors:  Martine J Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

3.  Metronomic therapy: it makes sense and is patient friendly.

Authors:  Barton A Kamen
Journal:  J Pediatr Hematol Oncol       Date:  2005-11       Impact factor: 1.289

4.  Low-dose metronomic chemotherapy: myth or truth?

Authors:  Sylvain Baruchel; Diana Stempak
Journal:  Onkologie       Date:  2006-07-03

Review 5.  The world of subinhibitory antibiotic concentrations.

Authors:  Julian Davies; George B Spiegelman; Grace Yim
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

Review 6.  Cell mechanics and stress: from molecular details to the 'universal cell reaction' and hormesis.

Authors:  Paul S Agutter
Journal:  Bioessays       Date:  2007-04       Impact factor: 4.345

Review 7.  Nonlinearity and thresholds in dose-response relationships for carcinogenicity due to sampling variation, logarithmic dose scaling, or small differences in individual susceptibility.

Authors:  W K Lutz; D W Gaylor; R B Conolly; R W Lutz
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-01       Impact factor: 4.219

Review 8.  The economics of cancer care in the UK.

Authors:  Nick Bosanquet; Karol Sikora
Journal:  Lancet Oncol       Date:  2004-09       Impact factor: 41.316

9.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

Authors:  Agustin A Garcia; Hal Hirte; Gini Fleming; Dongyun Yang; Denice D Tsao-Wei; Lynda Roman; Susan Groshen; Steve Swenson; Frank Markland; David Gandara; Sidney Scudder; Robert Morgan; Helen Chen; Heinz-Josef Lenz; Amit M Oza
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

10.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.

Authors:  Patrizia Mancuso; Marco Colleoni; Angelica Calleri; Laura Orlando; Patrick Maisonneuve; Giancarlo Pruneri; Alice Agliano; Aron Goldhirsch; Yuval Shaked; Robert S Kerbel; Francesco Bertolini
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

View more
  11 in total

1.  Practical implications of nanodosimetry in medicine.

Authors:  Jahangir A Satti
Journal:  Dose Response       Date:  2011-04-09       Impact factor: 2.658

2.  Testing the nanoparticle-allostatic cross-adaptation-sensitization model for homeopathic remedy effects.

Authors:  Iris R Bell; Mary Koithan; Audrey J Brooks
Journal:  Homeopathy       Date:  2013-01       Impact factor: 1.444

3.  Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation.

Authors:  Hoi-Hung Chan; Tian-Huei Chu; Hsin-Fan Chien; Cheuk-Kwan Sun; E-Ming Wang; Huay-Ben Pan; Hsiao-Mei Kuo; Tsung-Hui Hu; Kwok-Hung Lai; Jiin-Tsuey Cheng; Ming-Hong Tai
Journal:  BMC Gastroenterol       Date:  2010-07-22       Impact factor: 3.067

4.  Addition of bromelain and acetylcysteine to gemcitabine potentiates tumor inhibition in vivo in human colon cancer cell line LS174T.

Authors:  Ahmed H Mekkawy; Krishna Pillai; Samina Badar; Javed Akhter; Kevin Ke; Sarah J Valle; David L Morris
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

5.  Dose Response of MTLn3 Cells to Serial Dilutions of Arsenic Trioxide and Ionizing Radiation.

Authors:  Waseem Khan Raja; Jahangir Satti; Gang Liu; James Castracane
Journal:  Dose Response       Date:  2011-09-29       Impact factor: 2.658

6.  Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.

Authors:  L Manso; N Valdiviezo; J Sepúlveda; E Ciruelos; C Mendiola; I Ghanem; E Vega; R Manneh; M Dorta; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

7.  Modeling cancer-immune responses to therapy.

Authors:  L G dePillis; A Eladdadi; A E Radunskaya
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-04       Impact factor: 2.745

8.  Conceptualizing a tool to optimize therapy based on dynamic heterogeneity.

Authors:  David Liao; Luis Estévez-Salmerón; Thea D Tlsty
Journal:  Phys Biol       Date:  2012-11-29       Impact factor: 2.583

9.  Generalized principles of stochasticity can be used to control dynamic heterogeneity.

Authors:  David Liao; Luis Estévez-Salmerón; Thea D Tlsty
Journal:  Phys Biol       Date:  2012-11-29       Impact factor: 2.583

10.  An automated fitting procedure and software for dose-response curves with multiphasic features.

Authors:  Giovanni Y Di Veroli; Chiara Fornari; Ian Goldlust; Graham Mills; Siang Boon Koh; Jo L Bramhall; Frances M Richards; Duncan I Jodrell
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.